PharmaMar rises 3% after the United Kingdom sees its drug innovative – Faro de Vigo

PharmaMar’s share has experienced a rebound of more than 3% in yesterday’s session, after the Galician company announced that its drug Zepzelca (lurbinectedin) has received the Designation of Innovative Medicine (Innovation Passport) by the Regulatory Agency of Medicines and Health Products of the United Kingdom, as notified in a statement sent to the National Securities Market Commission (CNMV). Specifically, the pharmaceutical company’s shares have come to trade at a price of 63.3 euros, compared to 61.16 euros at the close of the previous day. At 2:10 p.m. Spanish peninsular time, the company’s share rose 1.5%, to stand at 62.08 euros. PharmaMar explained that the UK agency’s Innovative Licensing and Access Pathway (ILAP) aims to speed up time to market, facilitating patient access to medicines. ILAP comprises, as a first step, the designation of an Innovation Passport that supports innovative approaches for safe, timely and efficient drug development. Criteria for this designation include where the disease is life-threatening or seriously debilitating, or where there is a significant patient or public health need and where the drug has the potential to offer benefits to patients who take it.